250 related articles for article (PubMed ID: 34326169)
1. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA; Gheeya JS; Goswamy R; Bathala TK; Surasi DS; Gao J; Shah A; Campbell MT; Msaouel P; Goswami S; Wang J; Zurita AJ; Jonasch E; Corn PG; Aparicio AM; Siefker-Radtke AO; Sharma P; Subudhi SK; Tannir N
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326169
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
Nizam A; Rader RK; Tzeng A; Wei W; Sheng IY; Martin A; Wee CE; Gilligan TD; Gupta S; Ornstein MC
Clin Genitourin Cancer; 2024 Apr; 22(2):368-379. PubMed ID: 38245437
[TBL] [Abstract][Full Text] [Related]
3. Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer.
Kartolo A; Holstead R; Khalid S; Emack J; Hopman W; Baetz T
J Immunother; 2021 Jan; 44(1):41-48. PubMed ID: 32815895
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab Rechallenge After Immune-related Adverse Events in Patients With Unresectable Advanced or Recurrent Esophageal Cancer.
Ueno K; Suzuki K; Saito K; Shinohara H; Miura A
In Vivo; 2024; 38(2):794-799. PubMed ID: 38418136
[TBL] [Abstract][Full Text] [Related]
5. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma.
Shah P; Punekar SR; Pavlick AC
Melanoma Res; 2021 Jun; 31(3):242-248. PubMed ID: 33741813
[TBL] [Abstract][Full Text] [Related]
6. Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sanda GE; Shabto JM; Goyal S; Liu Y; Martini DJ; Nazha B; Brown JT; Yantorni LB; Anne Russler G; Caulfield S; Joshi SS; Narayan VM; Kissick H; Ogan K; Master VA; Carthon BC; Kucuk O; Bilen MA
Oncologist; 2023 Dec; 28(12):1072-1078. PubMed ID: 37285524
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-related adverse events: Real-world experience from a single veterans' affairs medical center.
Benz S; Sherman KA; Dasanu CA; Alvarez-Argote J
J Oncol Pharm Pract; 2024 Jun; 30(4):697-704. PubMed ID: 37350125
[TBL] [Abstract][Full Text] [Related]
8. Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study.
Ikoma T; Matsumoto T; Boku S; Motoki Y; Kinoshita H; Kosaka H; Kaibori M; Inoue K; Sekimoto M; Fujisawa T; Iwai H; Naganuma M; Tanizaki H; Hisamatsu Y; Okada H; Kurata T
Cancer Immunol Immunother; 2024 May; 73(7):126. PubMed ID: 38733406
[TBL] [Abstract][Full Text] [Related]
9. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.
Fujii T; Colen RR; Bilen MA; Hess KR; Hajjar J; Suarez-Almazor ME; Alshawa A; Hong DS; Tsimberidou A; Janku F; Gong J; Stephen B; Subbiah V; Piha-Paul SA; Fu S; Sharma P; Mendoza T; Patel A; Thirumurthi S; Sheshadri A; Meric-Bernstam F; Naing A
Invest New Drugs; 2018 Aug; 36(4):638-646. PubMed ID: 29159766
[TBL] [Abstract][Full Text] [Related]
10. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T; Kramer R; Forschner A; Leiter U; Meier F; Reinhardt L; Dücker P; Ertl C; Tomsitz D; Tietze JK; Gutzmer R; Dabrowski E; Zimmer L; Gesierich A; Zierold S; French LE; Eigentler T; Amaral T; Heinzerling L
Eur J Cancer; 2024 May; 203():114028. PubMed ID: 38652976
[TBL] [Abstract][Full Text] [Related]
11. Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses.
Blum SM; Rouhani SJ; Sullivan RJ
Immunol Rev; 2023 Sep; 318(1):167-178. PubMed ID: 37578634
[TBL] [Abstract][Full Text] [Related]
12. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM
Curti B; Daniels GA; McDermott DF; Clark JI; Kaufman HL; Logan TF; Singh J; Kaur M; Luna TL; Gregory N; Morse MA; Wong MKK; Dutcher JP
J Immunother Cancer; 2017 Dec; 5(1):102. PubMed ID: 29254506
[TBL] [Abstract][Full Text] [Related]
13. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer.
Zubiri L; Molina GE; Mooradian MJ; Cohen J; Durbin SM; Petrillo L; Boland GM; Juric D; Dougan M; Thomas MF; Faje AT; Rengarajan M; Guidon AC; Chen ST; Okin D; Medoff BD; Nasrallah M; Kohler MJ; Schoenfeld SR; Karp-Leaf RS; Sise ME; Neilan TG; Zlotoff DA; Farmer JR; Bardia A; Sullivan RJ; Blum SM; Semenov YR; Villani AC; Reynolds KL
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34544895
[TBL] [Abstract][Full Text] [Related]
14. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
Tyan K; Baginska J; Brainard M; Giobbie-Hurder A; Severgnini M; Manos M; Haq R; Buchbinder EI; Ott PA; Hodi FS; Rahma OE
Cancer Immunol Immunother; 2021 Aug; 70(8):2209-2221. PubMed ID: 33481042
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer.
He S; Wang L; Sun Y; Du H; Yu X
Front Immunol; 2023; 14():1270828. PubMed ID: 37915573
[TBL] [Abstract][Full Text] [Related]
16. Phenotyping Hepatic Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.
Feldman TC; Kaplan DE; Lin A; La J; Lee JSH; Aljehani M; Tuck DP; Brophy MT; Fillmore NR; Do NV
JCO Clin Cancer Inform; 2024 May; 8():e2300159. PubMed ID: 38728613
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma.
Miura Y; Motoshima T; Anami T; Yano H; Mito R; Pan C; Urakami S; Kinowaki K; Tsukamoto H; Kurahashi R; Murakami Y; Yatsuda J; Fujiwara Y; Kamba T; Komohara Y
Microbiol Immunol; 2023 Jul; 67(7):345-354. PubMed ID: 36975091
[TBL] [Abstract][Full Text] [Related]
18. Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers.
Cariou PL; Pobel C; Michot JM; Danlos FX; Besse B; Carbonnel F; Mariette X; Marabelle A; Messayke S; Robert C; Routier E; Noël N; Lambotte O
Eur J Cancer; 2024 Jun; 204():114065. PubMed ID: 38643707
[TBL] [Abstract][Full Text] [Related]
19. Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies.
Kim M; Chang CS; Choi MC; Lee JW; Park H; Joo WD
Yonsei Med J; 2023 Oct; 64(10):587-592. PubMed ID: 37727917
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-associated gastritis: Patterns and management.
Lin J; Lin ZQ; Zheng SC; Chen Y
World J Gastroenterol; 2024 Apr; 30(14):1941-1948. PubMed ID: 38681126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
